Ellen Burnham
Concepts (558)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcoholism | 39 | 2025 | 826 | 6.420 |
Why?
| | Respiratory Insufficiency | 11 | 2026 | 326 | 2.060 |
Why?
| | Bronchoalveolar Lavage Fluid | 22 | 2022 | 638 | 1.900 |
Why?
| | Intensive Care Units | 21 | 2025 | 924 | 1.800 |
Why?
| | Lung | 19 | 2025 | 4116 | 1.670 |
Why?
| | Alcohol-Related Disorders | 7 | 2015 | 121 | 1.600 |
Why?
| | Cannabis | 5 | 2025 | 510 | 1.280 |
Why?
| | Pneumonia | 9 | 2023 | 636 | 1.250 |
Why?
| | Ethanol | 11 | 2022 | 631 | 1.220 |
Why?
| | Acute Lung Injury | 10 | 2022 | 307 | 1.210 |
Why?
| | Respiratory Mucosa | 4 | 2020 | 322 | 1.190 |
Why?
| | Critical Illness | 21 | 2024 | 900 | 1.120 |
Why?
| | Marijuana Smoking | 3 | 2025 | 249 | 1.070 |
Why?
| | Hospitalization | 10 | 2025 | 2460 | 1.060 |
Why?
| | Sepsis | 6 | 2020 | 664 | 1.020 |
Why?
| | Gene Expression | 3 | 2020 | 1478 | 1.000 |
Why?
| | Macrophages, Alveolar | 9 | 2021 | 373 | 0.980 |
Why?
| | Patient Admission | 2 | 2025 | 220 | 0.970 |
Why?
| | Cytokines | 9 | 2025 | 2069 | 0.940 |
Why?
| | Middle Aged | 76 | 2026 | 36302 | 0.910 |
Why?
| | Critical Care | 10 | 2021 | 702 | 0.890 |
Why?
| | Survivors | 8 | 2025 | 523 | 0.870 |
Why?
| | Inflammation Mediators | 4 | 2016 | 507 | 0.850 |
Why?
| | Central Nervous System Depressants | 2 | 2021 | 84 | 0.810 |
Why?
| | Adult | 69 | 2025 | 40872 | 0.810 |
Why?
| | Pulmonary Alveoli | 6 | 2016 | 387 | 0.800 |
Why?
| | Acetates | 2 | 2021 | 78 | 0.800 |
Why?
| | Noninvasive Ventilation | 2 | 2024 | 62 | 0.790 |
Why?
| | Stem Cells | 5 | 2015 | 630 | 0.760 |
Why?
| | Humans | 134 | 2026 | 145763 | 0.760 |
Why?
| | Streptococcus pneumoniae | 2 | 2018 | 186 | 0.760 |
Why?
| | Smoking | 8 | 2021 | 1477 | 0.750 |
Why?
| | Pulmonary Fibrosis | 3 | 2022 | 395 | 0.750 |
Why?
| | Substance Withdrawal Syndrome | 4 | 2021 | 185 | 0.740 |
Why?
| | Mentors | 4 | 2014 | 217 | 0.730 |
Why?
| | Hospital Mortality | 7 | 2025 | 1038 | 0.730 |
Why?
| | Leukocytes, Mononuclear | 3 | 2017 | 574 | 0.730 |
Why?
| | Lung Diseases | 3 | 2021 | 782 | 0.720 |
Why?
| | Male | 84 | 2026 | 73003 | 0.700 |
Why?
| | Female | 86 | 2026 | 79035 | 0.690 |
Why?
| | Cerebrovascular Circulation | 2 | 2021 | 290 | 0.670 |
Why?
| | Behavior | 1 | 2021 | 90 | 0.650 |
Why?
| | Thalamus | 2 | 2021 | 129 | 0.630 |
Why?
| | Hypnotics and Sedatives | 4 | 2025 | 222 | 0.630 |
Why?
| | Glycerophospholipids | 4 | 2024 | 39 | 0.630 |
Why?
| | Case-Control Studies | 14 | 2022 | 3634 | 0.630 |
Why?
| | Respiration, Artificial | 13 | 2025 | 714 | 0.620 |
Why?
| | Burnout, Professional | 4 | 2022 | 488 | 0.600 |
Why?
| | Burns | 5 | 2025 | 374 | 0.600 |
Why?
| | Hallucinogens | 1 | 2021 | 111 | 0.590 |
Why?
| | Substance-Related Disorders | 2 | 2025 | 1102 | 0.580 |
Why?
| | Cigarette Smoking | 2 | 2020 | 102 | 0.570 |
Why?
| | RNA, Messenger | 5 | 2020 | 2805 | 0.560 |
Why?
| | Glutathione | 5 | 2016 | 370 | 0.560 |
Why?
| | Antioxidants | 4 | 2016 | 550 | 0.550 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2018 | 47 | 0.540 |
Why?
| | Tobacco Products | 1 | 2019 | 84 | 0.530 |
Why?
| | Toll-Like Receptor 2 | 2 | 2016 | 125 | 0.530 |
Why?
| | Epithelial Cells | 4 | 2021 | 1134 | 0.530 |
Why?
| | Xanthine Dehydrogenase | 1 | 2017 | 24 | 0.520 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 327 | 0.520 |
Why?
| | Opioid-Related Disorders | 2 | 2023 | 605 | 0.520 |
Why?
| | Physicians, Women | 1 | 2019 | 90 | 0.520 |
Why?
| | Inflammation | 8 | 2025 | 2883 | 0.510 |
Why?
| | Bronchoalveolar Lavage | 7 | 2023 | 89 | 0.510 |
Why?
| | Toll-Like Receptor 4 | 2 | 2016 | 276 | 0.480 |
Why?
| | Biomedical Research | 2 | 2021 | 719 | 0.480 |
Why?
| | Blood-Air Barrier | 2 | 2008 | 11 | 0.480 |
Why?
| | Organ Dysfunction Scores | 1 | 2016 | 55 | 0.470 |
Why?
| | Aged | 36 | 2026 | 26215 | 0.460 |
Why?
| | Marijuana Abuse | 1 | 2018 | 214 | 0.460 |
Why?
| | Alcohol Drinking | 6 | 2025 | 843 | 0.450 |
Why?
| | Biomarkers | 16 | 2026 | 4302 | 0.450 |
Why?
| | Retrospective Studies | 25 | 2025 | 17325 | 0.440 |
Why?
| | Azithromycin | 1 | 2015 | 101 | 0.440 |
Why?
| | Tomography | 2 | 2025 | 45 | 0.420 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2019 | 920 | 0.420 |
Why?
| | Electric Impedance | 2 | 2025 | 108 | 0.420 |
Why?
| | Research Support as Topic | 2 | 2011 | 81 | 0.410 |
Why?
| | Hypoxia | 4 | 2026 | 1199 | 0.400 |
Why?
| | Professional Autonomy | 1 | 2013 | 29 | 0.400 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 172 | 0.390 |
Why?
| | Cells, Cultured | 8 | 2018 | 4151 | 0.390 |
Why?
| | Tomography, X-Ray Computed | 2 | 2014 | 2770 | 0.380 |
Why?
| | Lipopolysaccharides | 5 | 2017 | 858 | 0.380 |
Why?
| | Bronchoscopy | 3 | 2023 | 227 | 0.380 |
Why?
| | Oxidative Stress | 5 | 2017 | 1359 | 0.370 |
Why?
| | Immunity, Innate | 1 | 2018 | 835 | 0.370 |
Why?
| | Asthma | 2 | 2022 | 1797 | 0.360 |
Why?
| | Drugs, Chinese Herbal | 1 | 2012 | 24 | 0.350 |
Why?
| | Academic Medical Centers | 2 | 2014 | 554 | 0.340 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2013 | 288 | 0.330 |
Why?
| | Imaging, Three-Dimensional | 2 | 2025 | 583 | 0.330 |
Why?
| | Venous Thromboembolism | 3 | 2020 | 328 | 0.320 |
Why?
| | Gene Expression Regulation | 6 | 2022 | 2601 | 0.320 |
Why?
| | Lymphoid Progenitor Cells | 1 | 2009 | 11 | 0.300 |
Why?
| | Malondialdehyde | 2 | 2021 | 31 | 0.300 |
Why?
| | Acetaldehyde | 2 | 2021 | 17 | 0.300 |
Why?
| | Muscular Diseases | 3 | 2017 | 109 | 0.300 |
Why?
| | United States | 18 | 2026 | 16123 | 0.300 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2010 | 98 | 0.300 |
Why?
| | Personnel Selection | 1 | 2011 | 91 | 0.300 |
Why?
| | Medical Staff, Hospital | 1 | 2010 | 80 | 0.300 |
Why?
| | Pneumococcal Infections | 1 | 2010 | 104 | 0.300 |
Why?
| | Cohort Studies | 13 | 2020 | 6032 | 0.290 |
Why?
| | Multiple Organ Failure | 3 | 2006 | 120 | 0.280 |
Why?
| | Anti-Bacterial Agents | 2 | 2019 | 1925 | 0.280 |
Why?
| | Smokers | 2 | 2021 | 138 | 0.280 |
Why?
| | Prevalence | 4 | 2025 | 2874 | 0.280 |
Why?
| | Epidemics | 2 | 2019 | 96 | 0.260 |
Why?
| | Pulmonary Embolism | 3 | 2019 | 241 | 0.260 |
Why?
| | Burns, Inhalation | 2 | 2017 | 9 | 0.260 |
Why?
| | Airway Extubation | 3 | 2013 | 60 | 0.260 |
Why?
| | Sexism | 2 | 2019 | 68 | 0.260 |
Why?
| | Betacoronavirus | 2 | 2020 | 289 | 0.250 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2018 | 1217 | 0.250 |
Why?
| | Benzodiazepines | 2 | 2025 | 168 | 0.250 |
Why?
| | Alcohol-Induced Disorders, Nervous System | 1 | 2006 | 7 | 0.250 |
Why?
| | Toll-Like Receptors | 2 | 2018 | 193 | 0.250 |
Why?
| | Naltrexone | 2 | 2025 | 115 | 0.250 |
Why?
| | Pilot Projects | 6 | 2025 | 1897 | 0.250 |
Why?
| | Multivariate Analysis | 5 | 2023 | 1547 | 0.250 |
Why?
| | Tissue Plasminogen Activator | 2 | 2018 | 248 | 0.240 |
Why?
| | Deglutition Disorders | 3 | 2013 | 154 | 0.240 |
Why?
| | Fibronectins | 1 | 2007 | 136 | 0.240 |
Why?
| | APACHE | 4 | 2013 | 68 | 0.240 |
Why?
| | Endothelial Cells | 4 | 2011 | 877 | 0.240 |
Why?
| | Practice Patterns, Physicians' | 2 | 2025 | 1372 | 0.240 |
Why?
| | Young Adult | 13 | 2024 | 14251 | 0.230 |
Why?
| | Marijuana Use | 2 | 2022 | 222 | 0.230 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2017 | 166 | 0.230 |
Why?
| | Administration, Inhalation | 3 | 2025 | 571 | 0.230 |
Why?
| | Immunity, Cellular | 2 | 2018 | 274 | 0.230 |
Why?
| | Preoperative Care | 1 | 2008 | 380 | 0.230 |
Why?
| | Polyunsaturated Alkamides | 1 | 2025 | 7 | 0.230 |
Why?
| | Risk Factors | 16 | 2020 | 10917 | 0.230 |
Why?
| | Anesthesiology | 1 | 2008 | 179 | 0.220 |
Why?
| | Tobacco Use Cessation | 1 | 2025 | 28 | 0.220 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 1197 | 0.220 |
Why?
| | Pediatrics | 1 | 2013 | 1125 | 0.220 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2005 | 57 | 0.220 |
Why?
| | Arachidonic Acids | 1 | 2025 | 42 | 0.220 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 391 | 0.220 |
Why?
| | Flow Cytometry | 2 | 2024 | 1165 | 0.220 |
Why?
| | Coronavirus Infections | 2 | 2020 | 384 | 0.220 |
Why?
| | Neuromuscular Blockade | 1 | 2025 | 53 | 0.220 |
Why?
| | tau Proteins | 1 | 2025 | 105 | 0.210 |
Why?
| | Propofol | 1 | 2025 | 85 | 0.210 |
Why?
| | Endocannabinoids | 1 | 2025 | 56 | 0.210 |
Why?
| | Dysbiosis | 2 | 2024 | 188 | 0.210 |
Why?
| | Immunity | 1 | 2025 | 140 | 0.210 |
Why?
| | E-Selectin | 1 | 2004 | 61 | 0.200 |
Why?
| | Patient Acceptance of Health Care | 3 | 2019 | 883 | 0.200 |
Why?
| | Bacterial Proteins | 1 | 2010 | 968 | 0.200 |
Why?
| | Patient Discharge | 3 | 2024 | 995 | 0.200 |
Why?
| | Quality of Life | 2 | 2013 | 3210 | 0.200 |
Why?
| | Immunophenotyping | 1 | 2024 | 322 | 0.200 |
Why?
| | Interleukin-1beta | 2 | 2017 | 389 | 0.190 |
Why?
| | Narcotic Antagonists | 1 | 2025 | 203 | 0.190 |
Why?
| | Central Nervous System | 1 | 2025 | 282 | 0.190 |
Why?
| | Drug Prescriptions | 1 | 2025 | 288 | 0.190 |
Why?
| | Anticoagulants | 2 | 2019 | 748 | 0.190 |
Why?
| | Aged, 80 and over | 10 | 2022 | 8346 | 0.190 |
Why?
| | Shock, Septic | 2 | 2022 | 227 | 0.190 |
Why?
| | Internship and Residency | 1 | 2013 | 1269 | 0.190 |
Why?
| | Interferons | 2 | 2016 | 186 | 0.190 |
Why?
| | Dyspnea | 2 | 2019 | 250 | 0.190 |
Why?
| | Polyneuropathies | 2 | 2017 | 57 | 0.190 |
Why?
| | Lung Injury | 2 | 2016 | 249 | 0.180 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 4 | 1 | 2022 | 22 | 0.180 |
Why?
| | Epithelium | 2 | 2021 | 311 | 0.180 |
Why?
| | Smoke Inhalation Injury | 2 | 2012 | 29 | 0.180 |
Why?
| | Age Factors | 4 | 2021 | 3346 | 0.170 |
Why?
| | Smoking Cessation | 1 | 2025 | 441 | 0.170 |
Why?
| | Delirium | 1 | 2023 | 105 | 0.170 |
Why?
| | Interleukin-8 | 3 | 2018 | 269 | 0.170 |
Why?
| | Fibroblasts | 3 | 2013 | 1027 | 0.170 |
Why?
| | Alcohol Abstinence | 1 | 2021 | 13 | 0.170 |
Why?
| | Double-Blind Method | 4 | 2014 | 2064 | 0.170 |
Why?
| | Societies, Medical | 2 | 2025 | 900 | 0.170 |
Why?
| | Cell Count | 2 | 2015 | 319 | 0.170 |
Why?
| | Critical Care Outcomes | 1 | 2020 | 11 | 0.170 |
Why?
| | Status Asthmaticus | 1 | 2020 | 13 | 0.170 |
Why?
| | Interleukin-6 | 3 | 2026 | 779 | 0.160 |
Why?
| | Neutrophils | 3 | 2017 | 1125 | 0.160 |
Why?
| | Feces | 1 | 2024 | 496 | 0.160 |
Why?
| | Phagocytosis | 2 | 2014 | 296 | 0.160 |
Why?
| | Rural Population | 1 | 2025 | 661 | 0.160 |
Why?
| | Physicians | 3 | 2022 | 956 | 0.160 |
Why?
| | Random Allocation | 1 | 2021 | 365 | 0.160 |
Why?
| | Pandemics | 4 | 2022 | 1711 | 0.160 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2018 | 337 | 0.160 |
Why?
| | Comorbidity | 4 | 2020 | 1662 | 0.150 |
Why?
| | Animals | 18 | 2025 | 38097 | 0.150 |
Why?
| | Immunoglobulin A | 1 | 2021 | 214 | 0.150 |
Why?
| | Permeability | 2 | 2012 | 169 | 0.150 |
Why?
| | Capacity Building | 1 | 2020 | 62 | 0.150 |
Why?
| | Career Choice | 2 | 2012 | 235 | 0.150 |
Why?
| | Chemokines | 2 | 2018 | 217 | 0.150 |
Why?
| | Analgesics, Opioid | 2 | 2025 | 1154 | 0.150 |
Why?
| | von Willebrand Factor | 1 | 2019 | 85 | 0.150 |
Why?
| | Homeostasis | 1 | 2003 | 644 | 0.150 |
Why?
| | Speech Therapy | 1 | 2019 | 21 | 0.150 |
Why?
| | Disaster Planning | 1 | 2020 | 103 | 0.140 |
Why?
| | Cardiology | 1 | 2022 | 362 | 0.140 |
Why?
| | Faculty, Medical | 1 | 2022 | 305 | 0.140 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2018 | 37 | 0.140 |
Why?
| | Macrolides | 1 | 2019 | 67 | 0.140 |
Why?
| | Needs Assessment | 1 | 2021 | 403 | 0.140 |
Why?
| | Endothelium, Vascular | 1 | 2005 | 956 | 0.140 |
Why?
| | Statistics, Nonparametric | 4 | 2014 | 428 | 0.140 |
Why?
| | Vecuronium Bromide | 1 | 2018 | 8 | 0.140 |
Why?
| | Atracurium | 1 | 2018 | 14 | 0.140 |
Why?
| | Brain | 3 | 2021 | 2969 | 0.140 |
Why?
| | Apoptosis | 3 | 2014 | 2443 | 0.140 |
Why?
| | Wounds and Injuries | 1 | 2006 | 962 | 0.140 |
Why?
| | Pyridines | 2 | 2010 | 609 | 0.140 |
Why?
| | Heart Failure, Diastolic | 1 | 2018 | 23 | 0.140 |
Why?
| | Community-Acquired Infections | 1 | 2020 | 177 | 0.140 |
Why?
| | Pulmonary Ventilation | 1 | 2018 | 82 | 0.130 |
Why?
| | Heart Failure, Systolic | 1 | 2018 | 26 | 0.130 |
Why?
| | Neuromuscular Blocking Agents | 1 | 2018 | 28 | 0.130 |
Why?
| | Cardiologists | 1 | 2018 | 45 | 0.130 |
Why?
| | Length of Stay | 4 | 2020 | 1350 | 0.130 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2022 | 390 | 0.130 |
Why?
| | Decision Making | 1 | 2025 | 982 | 0.130 |
Why?
| | Hospitals, University | 2 | 2015 | 176 | 0.130 |
Why?
| | Heparin | 1 | 2019 | 247 | 0.130 |
Why?
| | Chemokine CCL2 | 1 | 2017 | 112 | 0.130 |
Why?
| | Occupational Therapy | 1 | 2019 | 109 | 0.130 |
Why?
| | Interleukin-1 | 1 | 2001 | 961 | 0.130 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 979 | 0.120 |
Why?
| | Pyrazoles | 1 | 2001 | 517 | 0.120 |
Why?
| | Tobacco Use | 1 | 2017 | 62 | 0.120 |
Why?
| | Transforming Growth Factor beta | 3 | 2022 | 474 | 0.120 |
Why?
| | Cyclooxygenase 2 | 1 | 2017 | 167 | 0.120 |
Why?
| | Cystine | 1 | 2016 | 17 | 0.120 |
Why?
| | Factor Xa Inhibitors | 1 | 2018 | 194 | 0.120 |
Why?
| | Interleukin-10 | 1 | 2018 | 310 | 0.120 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2016 | 552 | 0.120 |
Why?
| | Feasibility Studies | 3 | 2026 | 1115 | 0.120 |
Why?
| | Disulfides | 1 | 2016 | 94 | 0.120 |
Why?
| | DNA, Bacterial | 1 | 2017 | 320 | 0.120 |
Why?
| | Immunosuppressive Agents | 1 | 2001 | 838 | 0.120 |
Why?
| | Treatment Outcome | 9 | 2022 | 11793 | 0.120 |
Why?
| | Disease Models, Animal | 4 | 2021 | 4568 | 0.120 |
Why?
| | Teichoic Acids | 1 | 2016 | 18 | 0.120 |
Why?
| | Hospitalists | 1 | 2020 | 267 | 0.120 |
Why?
| | Gastrointestinal Microbiome | 1 | 2024 | 768 | 0.120 |
Why?
| | Respiratory Tract Diseases | 1 | 2017 | 175 | 0.120 |
Why?
| | Follow-Up Studies | 3 | 2014 | 5428 | 0.120 |
Why?
| | Fibrinolytic Agents | 1 | 2018 | 297 | 0.110 |
Why?
| | Physical Therapy Modalities | 1 | 2019 | 337 | 0.110 |
Why?
| | RNA Splicing | 1 | 2017 | 284 | 0.110 |
Why?
| | Inflammasomes | 1 | 2017 | 144 | 0.110 |
Why?
| | Proteins | 2 | 2021 | 1023 | 0.110 |
Why?
| | Hospitals | 1 | 2020 | 733 | 0.110 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 100 | 0.110 |
Why?
| | Cysteine | 1 | 2016 | 211 | 0.110 |
Why?
| | Alternative Splicing | 1 | 2017 | 248 | 0.110 |
Why?
| | Urinary Bladder | 1 | 2017 | 196 | 0.110 |
Why?
| | Cannabinoids | 1 | 2017 | 184 | 0.110 |
Why?
| | Acetylcysteine | 1 | 2016 | 139 | 0.110 |
Why?
| | Patient Selection | 2 | 2023 | 739 | 0.110 |
Why?
| | Cholesterol | 1 | 2017 | 408 | 0.110 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2022 | 692 | 0.110 |
Why?
| | Interprofessional Relations | 1 | 2017 | 276 | 0.110 |
Why?
| | Signal Transduction | 3 | 2022 | 5223 | 0.110 |
Why?
| | Prospective Studies | 7 | 2026 | 8075 | 0.110 |
Why?
| | Oxidation-Reduction | 2 | 2016 | 1068 | 0.100 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2012 | 161 | 0.100 |
Why?
| | Severity of Illness Index | 5 | 2016 | 2933 | 0.100 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2014 | 62 | 0.100 |
Why?
| | Transcriptome | 1 | 2020 | 1042 | 0.100 |
Why?
| | Third-Party Consent | 1 | 2013 | 21 | 0.100 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1270 | 0.100 |
Why?
| | Professional Competence | 1 | 2014 | 91 | 0.100 |
Why?
| | Competency-Based Education | 1 | 2014 | 81 | 0.100 |
Why?
| | Chemokine CCL5 | 1 | 2013 | 40 | 0.100 |
Why?
| | Total Lung Capacity | 1 | 2013 | 29 | 0.100 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 420 | 0.100 |
Why?
| | Emergency Service, Hospital | 1 | 2025 | 2383 | 0.100 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2013 | 42 | 0.090 |
Why?
| | Reproducibility of Results | 3 | 2019 | 3416 | 0.090 |
Why?
| | Atherosclerosis | 1 | 2017 | 409 | 0.090 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2013 | 78 | 0.090 |
Why?
| | Financial Support | 1 | 2012 | 18 | 0.090 |
Why?
| | Disease Progression | 1 | 2020 | 2865 | 0.090 |
Why?
| | Interleukin-12 | 1 | 2013 | 115 | 0.090 |
Why?
| | Speech-Language Pathology | 1 | 2012 | 24 | 0.090 |
Why?
| | Logistic Models | 5 | 2017 | 2139 | 0.090 |
Why?
| | Quality Improvement | 1 | 2021 | 1296 | 0.090 |
Why?
| | Aging | 2 | 2017 | 1973 | 0.090 |
Why?
| | Transcription, Genetic | 2 | 2010 | 1454 | 0.090 |
Why?
| | Cell Survival | 1 | 2015 | 1103 | 0.090 |
Why?
| | Lymphatic Vessels | 1 | 2012 | 63 | 0.090 |
Why?
| | Informed Consent | 1 | 2013 | 199 | 0.090 |
Why?
| | Vital Capacity | 1 | 2013 | 292 | 0.090 |
Why?
| | Neuregulin-1 | 1 | 2012 | 49 | 0.090 |
Why?
| | Pepsin A | 1 | 2011 | 18 | 0.090 |
Why?
| | Acute Disease | 2 | 2025 | 1036 | 0.090 |
Why?
| | Serotonin | 1 | 2014 | 298 | 0.090 |
Why?
| | Ubiquitin | 1 | 2012 | 83 | 0.090 |
Why?
| | Chemokine CXCL12 | 1 | 2012 | 86 | 0.090 |
Why?
| | Phytotherapy | 1 | 2012 | 74 | 0.090 |
Why?
| | Lipid Peroxidation | 1 | 2012 | 168 | 0.090 |
Why?
| | Respiratory Aspiration | 1 | 2011 | 32 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 2 | 2021 | 3915 | 0.080 |
Why?
| | Respiratory Function Tests | 1 | 2013 | 544 | 0.080 |
Why?
| | MicroRNAs | 1 | 2017 | 686 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 849 | 0.080 |
Why?
| | Capillaries | 2 | 2009 | 125 | 0.080 |
Why?
| | Genetic Testing | 1 | 2013 | 483 | 0.080 |
Why?
| | Research Design | 2 | 2011 | 1139 | 0.080 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2011 | 78 | 0.080 |
Why?
| | Night Care | 1 | 2010 | 4 | 0.080 |
Why?
| | After-Hours Care | 1 | 2010 | 17 | 0.080 |
Why?
| | Nervous System Diseases | 1 | 2013 | 286 | 0.080 |
Why?
| | Awards and Prizes | 1 | 2011 | 71 | 0.080 |
Why?
| | Collagen | 1 | 2012 | 457 | 0.080 |
Why?
| | Autoantibodies | 1 | 2017 | 1509 | 0.080 |
Why?
| | Microbiota | 1 | 2017 | 730 | 0.080 |
Why?
| | ROC Curve | 2 | 2017 | 618 | 0.080 |
Why?
| | Colony-Forming Units Assay | 1 | 2009 | 95 | 0.080 |
Why?
| | Cell Differentiation | 2 | 2015 | 2050 | 0.080 |
Why?
| | Organizational Culture | 1 | 2011 | 162 | 0.080 |
Why?
| | Colorado | 5 | 2024 | 4556 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1582 | 0.070 |
Why?
| | Gastroesophageal Reflux | 1 | 2011 | 237 | 0.070 |
Why?
| | Program Development | 1 | 2011 | 368 | 0.070 |
Why?
| | Thyrotoxicosis | 1 | 2008 | 7 | 0.070 |
Why?
| | Peer Group | 1 | 2011 | 256 | 0.070 |
Why?
| | Mice | 7 | 2022 | 18355 | 0.070 |
Why?
| | Bayes Theorem | 2 | 2022 | 421 | 0.070 |
Why?
| | Technetium Tc 99m Pentetate | 1 | 2008 | 7 | 0.070 |
Why?
| | Computers | 1 | 2008 | 66 | 0.070 |
Why?
| | Hypertension, Pulmonary | 2 | 2011 | 1957 | 0.070 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 5992 | 0.070 |
Why?
| | Radionuclide Imaging | 1 | 2008 | 116 | 0.070 |
Why?
| | Half-Life | 1 | 2008 | 155 | 0.070 |
Why?
| | Focus Groups | 1 | 2011 | 572 | 0.070 |
Why?
| | Chest Pain | 1 | 2008 | 99 | 0.070 |
Why?
| | Burn Units | 2 | 2022 | 41 | 0.070 |
Why?
| | Quality Assurance, Health Care | 1 | 2010 | 342 | 0.070 |
Why?
| | Lung Transplantation | 1 | 2011 | 332 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2019 | 2028 | 0.070 |
Why?
| | Schools | 1 | 2011 | 449 | 0.070 |
Why?
| | Myeloid Cells | 1 | 2008 | 147 | 0.060 |
Why?
| | Radiopharmaceuticals | 1 | 2008 | 205 | 0.060 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2007 | 26 | 0.060 |
Why?
| | Cell Separation | 3 | 2016 | 306 | 0.060 |
Why?
| | Respiration Disorders | 1 | 2007 | 78 | 0.060 |
Why?
| | Staphylococcus aureus | 1 | 2011 | 453 | 0.060 |
Why?
| | Indicators and Reagents | 1 | 2007 | 106 | 0.060 |
Why?
| | Georgia | 2 | 2004 | 79 | 0.060 |
Why?
| | Cocaine-Related Disorders | 1 | 2008 | 133 | 0.060 |
Why?
| | Sex Factors | 1 | 2013 | 2110 | 0.060 |
Why?
| | NIH 3T3 Cells | 1 | 2007 | 145 | 0.060 |
Why?
| | Multicenter Studies as Topic | 2 | 2022 | 413 | 0.060 |
Why?
| | Thrombocytopenia | 2 | 2019 | 204 | 0.060 |
Why?
| | Body Fluids | 1 | 2007 | 71 | 0.060 |
Why?
| | Program Evaluation | 1 | 2011 | 944 | 0.060 |
Why?
| | Patient Readmission | 3 | 2019 | 772 | 0.060 |
Why?
| | Pulmonary Artery | 2 | 2013 | 1129 | 0.060 |
Why?
| | Stem Cell Transplantation | 1 | 2008 | 189 | 0.060 |
Why?
| | Nursing Staff, Hospital | 1 | 2009 | 143 | 0.060 |
Why?
| | Matrix Metalloproteinases | 1 | 2007 | 95 | 0.060 |
Why?
| | Lung Diseases, Interstitial | 1 | 2012 | 664 | 0.060 |
Why?
| | Cross-Sectional Studies | 4 | 2022 | 5922 | 0.060 |
Why?
| | Pneumonia, Bacterial | 1 | 2006 | 113 | 0.060 |
Why?
| | Propensity Score | 2 | 2017 | 377 | 0.060 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2025 | 68 | 0.060 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2025 | 122 | 0.050 |
Why?
| | Neurofilament Proteins | 1 | 2025 | 79 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2013 | 1997 | 0.050 |
Why?
| | Louisiana | 1 | 2024 | 31 | 0.050 |
Why?
| | Respiration | 1 | 2025 | 207 | 0.050 |
Why?
| | Observation | 1 | 2004 | 54 | 0.050 |
Why?
| | Adolescent | 6 | 2022 | 22573 | 0.050 |
Why?
| | Fatty Acids, Volatile | 1 | 2024 | 60 | 0.050 |
Why?
| | Dimercaprol | 1 | 2023 | 6 | 0.050 |
Why?
| | Hand Strength | 1 | 2024 | 144 | 0.050 |
Why?
| | Hemorrhage | 2 | 2019 | 822 | 0.050 |
Why?
| | Hydroxyethyl Starch Derivatives | 1 | 2003 | 9 | 0.050 |
Why?
| | Analgesia | 1 | 2024 | 106 | 0.050 |
Why?
| | Neoplasms | 1 | 2018 | 2913 | 0.050 |
Why?
| | Databases, Factual | 2 | 2019 | 1491 | 0.050 |
Why?
| | Time Factors | 4 | 2018 | 7133 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 6085 | 0.050 |
Why?
| | Nutritional Status | 1 | 2005 | 353 | 0.050 |
Why?
| | Body Surface Area | 1 | 2022 | 34 | 0.050 |
Why?
| | Adaptive Clinical Trials as Topic | 1 | 2022 | 24 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2022 | 75 | 0.050 |
Why?
| | Phosphoric Monoester Hydrolases | 1 | 2022 | 55 | 0.040 |
Why?
| | rhoA GTP-Binding Protein | 2 | 2014 | 76 | 0.040 |
Why?
| | Vasopressins | 1 | 2022 | 61 | 0.040 |
Why?
| | North America | 1 | 2022 | 303 | 0.040 |
Why?
| | rho-Associated Kinases | 2 | 2014 | 82 | 0.040 |
Why?
| | Receptors, Polymeric Immunoglobulin | 1 | 2021 | 2 | 0.040 |
Why?
| | Transcytosis | 1 | 2021 | 7 | 0.040 |
Why?
| | Norepinephrine | 1 | 2022 | 201 | 0.040 |
Why?
| | Blood Alcohol Content | 1 | 2021 | 6 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 361 | 0.040 |
Why?
| | Vasoconstrictor Agents | 1 | 2022 | 150 | 0.040 |
Why?
| | Hedgehog Proteins | 1 | 2022 | 200 | 0.040 |
Why?
| | Cilia | 1 | 2022 | 172 | 0.040 |
Why?
| | Bleomycin | 1 | 2022 | 255 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2021 | 3130 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 668 | 0.040 |
Why?
| | Containment of Biohazards | 1 | 2020 | 23 | 0.040 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2009 | 890 | 0.040 |
Why?
| | Recombinant Proteins | 2 | 2015 | 1368 | 0.040 |
Why?
| | Rats | 2 | 2017 | 5585 | 0.040 |
Why?
| | Intersectoral Collaboration | 1 | 2020 | 64 | 0.040 |
Why?
| | Protein Transport | 1 | 2021 | 442 | 0.040 |
Why?
| | Chronic Disease | 3 | 2015 | 1812 | 0.040 |
Why?
| | Incidence | 2 | 2003 | 2933 | 0.040 |
Why?
| | Prognosis | 3 | 2013 | 4329 | 0.040 |
Why?
| | Pharmacoepidemiology | 1 | 2019 | 23 | 0.040 |
Why?
| | Medical Oncology | 1 | 2022 | 340 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2019 | 172 | 0.040 |
Why?
| | Fellowships and Scholarships | 1 | 2022 | 354 | 0.030 |
Why?
| | Coronary Circulation | 1 | 2018 | 134 | 0.030 |
Why?
| | Hospitals, Rural | 1 | 2018 | 49 | 0.030 |
Why?
| | Illinois | 1 | 2017 | 49 | 0.030 |
Why?
| | Leadership | 1 | 2022 | 402 | 0.030 |
Why?
| | Hospital Charges | 1 | 2017 | 46 | 0.030 |
Why?
| | Phenotype | 1 | 2026 | 3170 | 0.030 |
Why?
| | RNA Transport | 1 | 2017 | 27 | 0.030 |
Why?
| | Hospitals, Urban | 1 | 2018 | 142 | 0.030 |
Why?
| | Qualitative Research | 1 | 2025 | 1683 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2018 | 169 | 0.030 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2017 | 88 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 2022 | 719 | 0.030 |
Why?
| | Administration, Oral | 1 | 2019 | 867 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2018 | 770 | 0.030 |
Why?
| | Algorithms | 1 | 2024 | 1850 | 0.030 |
Why?
| | Venous Thrombosis | 1 | 2019 | 196 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2017 | 334 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2025 | 1420 | 0.030 |
Why?
| | Sex Distribution | 1 | 2017 | 388 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2967 | 0.030 |
Why?
| | Dried Blood Spot Testing | 1 | 2017 | 126 | 0.030 |
Why?
| | RNA Precursors | 1 | 2017 | 154 | 0.030 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 1 | 2016 | 31 | 0.030 |
Why?
| | Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 1 | 2015 | 4 | 0.030 |
Why?
| | Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2015 | 8 | 0.030 |
Why?
| | Capillary Leak Syndrome | 1 | 2015 | 12 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2008 | 2977 | 0.030 |
Why?
| | Cell Communication | 1 | 2017 | 327 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 450 | 0.030 |
Why?
| | Risk | 1 | 2018 | 923 | 0.030 |
Why?
| | Interferon-alpha | 1 | 2016 | 193 | 0.030 |
Why?
| | Capillary Permeability | 1 | 2016 | 132 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2017 | 266 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 849 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 508 | 0.030 |
Why?
| | Cause of Death | 1 | 2017 | 471 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 947 | 0.030 |
Why?
| | Ventricular Function, Left | 1 | 2018 | 544 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2015 | 247 | 0.030 |
Why?
| | Interleukin-4 | 1 | 2015 | 207 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 778 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1271 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2123 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 971 | 0.030 |
Why?
| | Gastrointestinal Tract | 1 | 2016 | 204 | 0.030 |
Why?
| | Mental Competency | 1 | 2013 | 27 | 0.020 |
Why?
| | Odds Ratio | 1 | 2016 | 1083 | 0.020 |
Why?
| | Catheterization, Swan-Ganz | 1 | 2013 | 9 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2014 | 330 | 0.020 |
Why?
| | Phylogeny | 1 | 2017 | 917 | 0.020 |
Why?
| | Ventilator Weaning | 1 | 2013 | 40 | 0.020 |
Why?
| | Survival Analysis | 1 | 2016 | 1378 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor D | 1 | 2012 | 13 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor C | 1 | 2012 | 16 | 0.020 |
Why?
| | Lymphangiogenesis | 1 | 2012 | 27 | 0.020 |
Why?
| | Thymus Gland | 1 | 2014 | 312 | 0.020 |
Why?
| | Tidal Volume | 1 | 2013 | 109 | 0.020 |
Why?
| | Biological Transport | 1 | 2014 | 424 | 0.020 |
Why?
| | Fibrosis | 1 | 2015 | 561 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2015 | 731 | 0.020 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2012 | 148 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2013 | 155 | 0.020 |
Why?
| | Observer Variation | 1 | 2012 | 357 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2015 | 529 | 0.020 |
Why?
| | Bronchiolitis Obliterans | 1 | 2011 | 61 | 0.020 |
Why?
| | Protein Binding | 1 | 2017 | 2240 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2017 | 2525 | 0.020 |
Why?
| | Nanoparticles | 1 | 2017 | 517 | 0.020 |
Why?
| | Healthcare Disparities | 1 | 2018 | 736 | 0.020 |
Why?
| | Microbial Viability | 1 | 2011 | 83 | 0.020 |
Why?
| | World Health Organization | 1 | 2011 | 104 | 0.020 |
Why?
| | Superoxides | 1 | 2011 | 198 | 0.020 |
Why?
| | Research Personnel | 1 | 2012 | 185 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2012 | 428 | 0.020 |
Why?
| | Extracellular Matrix | 1 | 2015 | 562 | 0.020 |
Why?
| | Proteomics | 1 | 2017 | 1188 | 0.020 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 264 | 0.020 |
Why?
| | Immunomodulation | 1 | 2011 | 99 | 0.020 |
Why?
| | Radiography | 1 | 2012 | 853 | 0.020 |
Why?
| | Species Specificity | 1 | 2011 | 546 | 0.020 |
Why?
| | Blood Pressure | 1 | 2017 | 1782 | 0.020 |
Why?
| | rho GTP-Binding Proteins | 1 | 2010 | 56 | 0.020 |
Why?
| | Amides | 1 | 2010 | 101 | 0.020 |
Why?
| | Injury Severity Score | 1 | 2012 | 599 | 0.020 |
Why?
| | Autoimmune Diseases | 1 | 2014 | 469 | 0.020 |
Why?
| | Cell Death | 1 | 2011 | 382 | 0.020 |
Why?
| | Phosphorylation | 1 | 2014 | 1708 | 0.020 |
Why?
| | Lung Compliance | 1 | 2009 | 42 | 0.020 |
Why?
| | Metabolomics | 1 | 2015 | 733 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1777 | 0.020 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2011 | 237 | 0.020 |
Why?
| | Biopsy | 1 | 2012 | 1082 | 0.020 |
Why?
| | Viruses | 1 | 2011 | 166 | 0.020 |
Why?
| | Physician-Nurse Relations | 1 | 2009 | 18 | 0.020 |
Why?
| | Leisure Activities | 1 | 2009 | 31 | 0.020 |
Why?
| | AC133 Antigen | 1 | 2008 | 20 | 0.020 |
Why?
| | Cell Fusion | 1 | 2008 | 48 | 0.020 |
Why?
| | Giant Cells | 1 | 2008 | 21 | 0.020 |
Why?
| | Triiodothyronine | 1 | 2008 | 55 | 0.020 |
Why?
| | Leukocyte Common Antigens | 1 | 2008 | 87 | 0.020 |
Why?
| | Thyroxine | 1 | 2008 | 67 | 0.020 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2009 | 80 | 0.020 |
Why?
| | Mitochondria | 1 | 2015 | 992 | 0.020 |
Why?
| | Nurse Administrators | 1 | 2009 | 42 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 782 | 0.020 |
Why?
| | Osteocytes | 1 | 2008 | 24 | 0.020 |
Why?
| | Breath Tests | 1 | 2007 | 77 | 0.020 |
Why?
| | Clone Cells | 1 | 2008 | 263 | 0.020 |
Why?
| | Databases as Topic | 1 | 2007 | 71 | 0.020 |
Why?
| | Child | 2 | 2022 | 22739 | 0.020 |
Why?
| | Social Environment | 1 | 2009 | 252 | 0.020 |
Why?
| | Curriculum | 1 | 2014 | 1074 | 0.020 |
Why?
| | Laparoscopy | 1 | 2011 | 481 | 0.020 |
Why?
| | Health Surveys | 1 | 2009 | 520 | 0.020 |
Why?
| | Cell Movement | 1 | 2011 | 961 | 0.020 |
Why?
| | Glycoproteins | 1 | 2008 | 354 | 0.020 |
Why?
| | Models, Biological | 1 | 2014 | 1764 | 0.020 |
Why?
| | Job Satisfaction | 1 | 2009 | 238 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2007 | 532 | 0.010 |
Why?
| | Adipocytes | 1 | 2008 | 223 | 0.010 |
Why?
| | Hydrogen Peroxide | 1 | 2007 | 335 | 0.010 |
Why?
| | Trauma Centers | 1 | 2009 | 466 | 0.010 |
Why?
| | Cell Lineage | 1 | 2008 | 378 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2012 | 1751 | 0.010 |
Why?
| | Telomerase | 1 | 2008 | 246 | 0.010 |
Why?
| | Chondrocytes | 1 | 2008 | 232 | 0.010 |
Why?
| | Antigens, CD | 1 | 2008 | 558 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2008 | 1512 | 0.010 |
Why?
| | Health Care Costs | 1 | 2007 | 425 | 0.010 |
Why?
| | France | 1 | 2003 | 40 | 0.010 |
Why?
| | Contraindications | 1 | 2003 | 90 | 0.010 |
Why?
| | Peptides | 1 | 2008 | 998 | 0.010 |
Why?
| | Washington | 1 | 2003 | 149 | 0.010 |
Why?
| | Cardiac Output | 1 | 2003 | 179 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2008 | 2514 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2003 | 1300 | 0.010 |
Why?
|
|
Burnham's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|